logo

Centrum Wsparcia Badań Klinicznych – CWBK (Clinical Trials Support Center) of the National Institute of Geriatrics, Rheumatology and Rehabilitation (NIGRiR) is a site conducting clinical trials in fields such as: rheumatology, immunology, neurology, cardiology, orthopedics, rehabilitation, pulmonology, and dermatology. In our modern center, clinical trials are conducted at the highest standard and with maximum comfort for patients.

CWBK, as a highly specialized unit, conducts clinical trials for patients from all over Poland, with particular attention to those who present diagnostic and therapeutic challenges, for whom participation in clinical trials may be the only chance to improve health, slow disease progression, or achieve remission.

The mission of CWBK’s experienced medical teams – doctors and nurses – is to ensure patients have access to modern forms of treatment, improving their health and quality of life, while maintaining the highest global standards of safety and respect for patient rights. The medical staff at CWBK is supported by a team of qualified administrative professionals experienced in managing medical and laboratory documentation in accordance with Good Clinical Practice (GCP) guidelines.

CWBK is actively involved in scientific and clinical initiatives with national and international research communities, paving the way for new projects, diagnostic methods, and future treatment solutions – namely, personalized medicine. The opportunity for these patients to participate in clinical trials not only opens access to drugs and therapies not financed by the National Health Fund (NFZ) but also reduces the cost of accessing and delivering treatment.

Verificato
Valutazioni elevate
30+ Specializzazioni
60+ Terapie
Fase di ricerca I

Informazioni sulle specializzazioni

Sede del centro medico

Ul. Spartanska 1
02-637 Varsavia, Polonia

Vuoi saperne di più su questo studio o verificare se puoi partecipare? Contattaci.

Studi in corso

  • Studio sull’efficacia di filgotinib in pazienti adulti con spondiloartrite assiale attiva

    Arruolamento concluso

    1 1 1 1
    Malattie in studio:
    Farmaci in studio:
    Belgio Bulgaria Croazia Cechia Estonia Francia +9
  • Studio sull’efficacia di Secukinumab e Prednisone in pazienti con polimialgia reumatica recentemente recidivata

    Arruolamento concluso

    1 1 1 1
    Farmaci in studio:
    Belgio Cechia Danimarca Finlandia Francia Germania +9
  • Studio sull’efficacia e sicurezza di RHH646 per pazienti con osteoartrite del ginocchio

    Arruolamento concluso

    1 1
    Farmaci in studio:
    Danimarca Germania Polonia Spagna
  • Studio sull’efficacia e sicurezza di Milvexian rispetto ad Apixaban in pazienti con Fibrillazione Atriale

    Arruolamento concluso

    1 1 1
    Belgio Bulgaria Croazia Cechia Danimarca Estonia +13
  • Studio sulla Sicurezza ed Efficacia di ESK-001 in Pazienti Adulti con Lupus Eritematoso Sistemico

    Arruolamento concluso

    1 1
    Farmaci in studio:
    Bulgaria Croazia Danimarca Germania Ungheria Polonia +2
  • Studio sull’Efficacia e Sicurezza di HZN-1116 nei Pazienti con Sindrome di Sjögren

    Arruolamento concluso

    Farmaci in studio:
    Austria Bulgaria Francia Germania Grecia Ungheria +5
  • Studio sull’efficacia di nintedanib e tocilizumab in pazienti con sclerosi sistemica e malattia polmonare interstiziale

    Arruolamento concluso

    1 1 1 1 1
    Farmaci in studio:
    Polonia
  • Studio sull’efficacia e sicurezza di bimekizumab rispetto a risankizumab in adulti con artrite psoriasica attiva

    Arruolamento concluso

    1 1 1
    Farmaci in studio:
    Bulgaria Cechia Germania Ungheria Polonia Spagna